151 related articles for article (PubMed ID: 34673582)
1. Malignant mesothelioma: A clinicopathological study of 76 cases with emphasis on immunohistochemical evaluation along with review of the literature.
Patel T; Aswal P
Indian J Pathol Microbiol; 2021; 64(4):655-663. PubMed ID: 34673582
[TBL] [Abstract][Full Text] [Related]
2. Malignant mesothelioma: A histomorphological and immunohistochemical study of 24 cases from a tertiary care hospital in Southern India.
Hui M; Uppin SG; Bhaskar K; Kumar NN; Paramjyothi GK
Indian J Cancer; 2018; 55(2):190-195. PubMed ID: 30604735
[TBL] [Abstract][Full Text] [Related]
3. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic Utility of BAP1, EZH2 and Survivin in Differentiating Pleural Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia: Immunohistochemical Study.
Hakim SA; Abou Gabal HH
Pathol Oncol Res; 2021; 27():600073. PubMed ID: 34257556
[No Abstract] [Full Text] [Related]
5. Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations.
Sejben A; Pancsa T; Tiszlavicz L; Furák J; Paróczai D; Zombori T
Thorac Cancer; 2023 Apr; 14(10):857-863. PubMed ID: 36808895
[TBL] [Abstract][Full Text] [Related]
6. Cytological Diagnosis of Malignant Mesothelioma: A Case Series.
Dahiya S; Singh M; Jain S; Khuraijam B; Suroya N; Mandal S
J Cytol; 2022; 39(3):105-109. PubMed ID: 36277806
[TBL] [Abstract][Full Text] [Related]
7. Re-evaluation of histological diagnoses of malignant mesothelioma by immunohistochemistry.
Sandeck HP; Røe OD; Kjærheim K; Willén H; Larsson E
Diagn Pathol; 2010 Jul; 5():47. PubMed ID: 20602796
[TBL] [Abstract][Full Text] [Related]
8. New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.
Galateau Salle F; Le Stang N; Nicholson AG; Pissaloux D; Churg A; Klebe S; Roggli VL; Tazelaar HD; Vignaud JM; Attanoos R; Beasley MB; Begueret H; Capron F; Chirieac L; Copin MC; Dacic S; Danel C; Foulet-Roge A; Gibbs A; Giusiano-Courcambeck S; Hiroshima K; Hofman V; Husain AN; Kerr K; Marchevsky A; Nabeshima K; Picquenot JM; Rouquette I; Sagan C; Sauter JL; Thivolet F; Travis WD; Tsao MS; Weynand B; Damiola F; Scherpereel A; Pairon JC; Lantuejoul S; Rusch V; Girard N
J Thorac Oncol; 2018 Aug; 13(8):1189-1203. PubMed ID: 29723687
[TBL] [Abstract][Full Text] [Related]
9. Role of Cytology in the Current Guidelines for Malignant Mesothelioma: Largest Study from India.
Kaur K; Patel T; Samanta S; Patra S; Trivedi P
Acta Cytol; 2021; 65(2):175-185. PubMed ID: 33316798
[TBL] [Abstract][Full Text] [Related]
10. Histopathological and immunohistochemical features of 14 peritoneal mesotheliomas with clinical outcomes and recent updates.
Karmarkar S; Rekhi B; Deodhar KK; Menon S
J Cancer Res Ther; 2022; 18(6):1683-1691. PubMed ID: 36412430
[TBL] [Abstract][Full Text] [Related]
11. Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.
Capkova L; Koubkova L; Kodet R
Neoplasma; 2014; 61(2):161-9. PubMed ID: 24471939
[TBL] [Abstract][Full Text] [Related]
12. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma.
Miettinen M; Limon J; Niezabitowski A; Lasota J
Am J Surg Pathol; 2001 May; 25(5):610-7. PubMed ID: 11342772
[TBL] [Abstract][Full Text] [Related]
13. How to assess the best immunohistochemical panel in the diagnosis of malignant pleural mesothelioma in a pathology lab.
Mlika M; Lamzibri O; Bacha S; Laabidi S; Haddouchi C; Mezni FE
J Immunoassay Immunochem; 2018; 39(3):263-273. PubMed ID: 29757709
[TBL] [Abstract][Full Text] [Related]
14. Sarcomatoid Mesothelioma: A Clinicopathological and Immunohistochemical Study of 64 Cases.
Oramas DM; Zaleski M; Moran CA
Int J Surg Pathol; 2021 Dec; 29(8):820-825. PubMed ID: 33939493
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical diagnosis of epithelioid mesothelioma: an update.
Ordóñez NG
Arch Pathol Lab Med; 2005 Nov; 129(11):1407-14. PubMed ID: 16253021
[TBL] [Abstract][Full Text] [Related]
16. Deciduoid mesothelioma: report of 21 cases with review of the literature.
Ordóñez NG
Mod Pathol; 2012 Nov; 25(11):1481-95. PubMed ID: 22684220
[TBL] [Abstract][Full Text] [Related]
17. Pleural Mesothelioma: Current Practice and Approach.
Lenskaya V; Moran CA
Adv Anat Pathol; 2023 Jul; 30(4):243-252. PubMed ID: 36689647
[TBL] [Abstract][Full Text] [Related]
18. [Clinicopathological characteristics and prognosis of malignant pleural mesothelioma].
Chen WH; Zhang XL; Dai HP; Tong ZH; Zhang YH; Jin ML
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Nov; 36(11):825-8. PubMed ID: 24507393
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of clinicopathological features of 68 cases of malignant pleural mesothelioma].
Mei W; Yang SJ; Zhang YP; Fu QS; Xiong W; Zhao Y
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Aug; 41(8):588-593. PubMed ID: 37667154
[No Abstract] [Full Text] [Related]
20. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses.
Kawai T; Tominaga S; Hiroi S; Ogata S; Nakanishi K; Kawahara K; Sonobe H; Hiroshima K
J Clin Pathol; 2016 Aug; 69(8):706-12. PubMed ID: 26729015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
